Healthcare provider profile · identity verified

Julie Ryan Blankemeier, MD

Family Practice · BERWYN, IL · NPI 1801101555

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	902	277
Lisinopril	Lisinopril	271	86
Amlodipine Besylate	Amlodipine Besylate	259	85
Metformin Hcl	Metformin Hcl	256	86
Losartan Potassium	Losartan Potassium	223	69
Hydrochlorothiazide	Hydrochlorothiazide	216	76
Metoprolol Succinate	Metoprolol Succinate	164	46
Jardiance	Empagliflozin	160	53
Levothyroxine Sodium	Levothyroxine Sodium	143	37
Duloxetine Hcl	Duloxetine Hcl	118	35
Fluticasone Propionate	Fluticasone Propionate	112	45
Tamsulosin Hcl	Tamsulosin Hcl	112	37
Gabapentin	Gabapentin	106	41
Albuterol Sulfate Hfa	Albuterol Sulfate	104	39
Sertraline Hcl	Sertraline Hcl	93	34
Alendronate Sodium	Alendronate Sodium	89	29
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	86	25
Enalapril Maleate	Enalapril Maleate	82	21
Ezetimibe	Ezetimibe	80	21
Omeprazole	Omeprazole	80	31
Arexvy	Rsvpref3 Antigen/As01e/Pf	79	79
Furosemide	Furosemide	78	29
Triamcinolone Acetonide	Triamcinolone Acetonide	74	35
Diclofenac Sodium	Diclofenac Sodium	67	42
Metformin Hcl Er	Metformin Hcl	65	18
Ozempic	Semaglutide	60	16
Simvastatin	Simvastatin	60	19
Finasteride	Finasteride	52	19
Pravastatin Sodium	Pravastatin Sodium	52	20
Shingrix	Varicella-Zoster Ge/As01b/Pf	52	50
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	51	51
Eliquis	Apixaban	45	13
Pantoprazole Sodium	Pantoprazole Sodium	45	17
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	44	30
Rosuvastatin Calcium	Rosuvastatin Calcium	43	17
Famotidine	Famotidine	42	19
Soliqua 100-33	Insulin Glargine/Lixisenatide	39	suppressed
Glipizide Er	Glipizide	38	16
Carvedilol	Carvedilol	37	13
Potassium Chloride	Potassium Chloride	37	14
Clopidogrel	Clopidogrel Bisulfate	36	14
Escitalopram Oxalate	Escitalopram Oxalate	36	13
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	36	12
Trulicity	Dulaglutide	34	suppressed
Spironolactone	Spironolactone	31	13
Nifedipine Er	Nifedipine	29	suppressed
Trazodone Hcl	Trazodone Hcl	29	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	28	suppressed
Rybelsus	Semaglutide	27	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	26	suppressed
Montelukast Sodium	Montelukast Sodium	26	suppressed
Hydralazine Hcl	Hydralazine Hcl	25	suppressed
Novolog Flexpen	Insulin Aspart	25	11
Benazepril Hcl	Benazepril Hcl	24	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	23	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	23	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	22	suppressed
Clonidine Hcl	Clonidine Hcl	20	suppressed
Meclizine Hcl	Meclizine Hcl	19	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	18	suppressed
Prednisone	Prednisone	18	14
Valsartan	Valsartan	18	suppressed
Farxiga	Dapagliflozin Propanediol	17	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	17	suppressed
Myrbetriq	Mirabegron	17	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Tramadol Hcl	Tramadol Hcl	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	15
Glimepiride	Glimepiride	15	suppressed
Naproxen	Naproxen	15	14
Torsemide	Torsemide	15	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Allopurinol	Allopurinol	14	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Irbesartan	Irbesartan	14	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	13	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Glipizide	Glipizide	12	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Tradjenta	Linagliptin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error